Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Aalborg Universitets forskningsportal Hjem
Dansk
English
Hjem
Profiler
Projekter
Publikationer
Aktiviteter
Forskningsenheder
Faciliteter
Presse/medier
Priser
Forskningsdatasæt
Impacts
Søg efter ekspertise, navn eller tilknytning
Vis Scopus-profil
Jens Aarøe
Aalborg Universitetshospital
Det Sundhedsvidenskabelige Fakultet
Overlæge
,
Hjertemedicinsk Afdeling
E-mail
jensaaroe
rn
dk
2002
2023
Publikationer pr. år
Vis
Fingerprint
Netværk
Publikationer
(80)
Priser
(1)
Aktiviteter
(16)
Presse/medier
(1)
Lignende profiler
(6)
Fingerprint
Dyk ned i forskningsemnerne, hvor Jens Aarøe er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
Sorter
Vægt
Alfabetisk
Medicine and Dentistry
Rapamycin
100%
Percutaneous Coronary Intervention
74%
Stenting
60%
ST Segment Elevation Myocardial Infarction
60%
Umirolimus
51%
Primary Percutaneous Coronary Intervention
47%
Myocardial Infarction
42%
Coronary Artery
40%
Stent Thrombosis
38%
Drug-Eluting Stent
32%
Percutaneous Aortic Valve Replacement
29%
Major Adverse Cardiac Event
29%
Diabetes Mellitus
28%
Target Lesion
27%
Noninferiority Trial
26%
Heart Death
26%
Coronary Bifurcation Lesion
25%
Diabetes
25%
Everolimus
22%
Telerehabilitation
22%
Randomized Controlled Trial
22%
Target Lesion Revascularization
21%
Revascularization
19%
Hazard Ratio
19%
Angiography
17%
Acute Heart Infarction
17%
Intention-to-Treat Analysis
16%
Embolization
15%
off Pump Coronary Surgery
14%
Intravascular Ultrasound
14%
Elderly Patient
14%
Target Vessel Revascularization
13%
Apoplexy
13%
Coronary Angiography
12%
Infarction
12%
Non ST Segment Elevation Myocardial Infarction
12%
Coronary Artery Disease
12%
Odds Ratio
11%
Quality of Life
11%
Graft Patency
11%
Attributable Risk
10%
Artery
10%
Coronary Artery Bypass Graft
9%
Heart Failure
9%
Cardiovascular Disease
9%
All Cause Mortality
8%
Adverse Event
8%
Diseases
8%
Patient with Diabetes
8%
Cardiac Magnetic Resonance Imaging
8%
Keyphrases
Sirolimus
30%
Zotarolimus
29%
Clinical Outcome
25%
Coronary Stent
22%
Biodegradable Polymers
22%
Zotarolimus-eluting Stent
20%
Sirolimus-eluting Stent
17%
Superiority Trials
14%
Biolimus
14%
Durable Polymer
14%
ST-elevation Myocardial Infarction (STEMI)
14%
Primary Percutaneous Coronary Intervention
14%
Ischemic Preconditioning
14%
Percutaneous Coronary Intervention
13%
Hazard Ratio
12%
Stent Thrombosis
11%
Target Lesion Revascularization
11%
Myocardial Infarction
11%
Stent Implantation
11%
Biodegradable Polymer Biolimus-eluting Stents
11%
Diabetes
11%
Adverse Cardiac Events
10%
Biolimus-eluting Stent
9%
Confidence Interval
9%
Non-inferiority Trial
9%
Drug-eluting Stent
9%
Stent
8%
Coronary Stent Implantation
8%
Infarct-related Artery
8%
Cardiac Death
8%
Diabetes Mellitus
7%
Polymer-coated
7%
Polymeric Stent
7%
Incomplete Stent Apposition
7%
Stent Fracture
7%
Stent Treatment
7%
Intravascular Ultrasound
7%
Patients with Diabetes
7%
Complex Stenting
7%
Bifurcation Study
7%
Coronary Artery Bifurcation Lesion
7%
Coronary Artery Stenting
7%
Low-density Lipoprotein Particle
7%
CT-based
7%
IMPACT Trial
7%
Without Diabetes
7%
Intracoronary
7%
Surgery in the Elderly
7%
On-pump
7%
Graft Patency
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
48%
ST Segment Elevation Myocardial Infarction
39%
Umirolimus
37%
Stent Thrombosis
18%
Coronary Artery Disease
17%
Heart Infarction
16%
Paclitaxel
14%
Melatonin
14%
Zotarolimus
14%
Everolimus
14%
Infarction
14%
Reperfusion Injury
14%
Heart Death
11%
Noninferiority Trial
11%
Major Adverse Cardiac Event
9%
Coronary Bifurcation Lesion
9%
Acute Heart Infarction
8%
All Cause Mortality
8%
Heart Failure
8%
Case-Control Study
7%
Randomized Clinical Trial
7%
Disease
7%
Coronary Artery Atherosclerosis
7%
Taxus
7%
Low Density Lipoprotein
7%
Randomized Controlled Trial
7%
Mortality Rate
7%
Regadenoson
7%
CD34 Antibody
7%
Cardiovascular Mortality
7%